It takes somewhere between 10 and 15 years—and possibly up to 25—after quitting tobacco for former heavy smokers’ CVD risk to revert to pre-smoking levels, according to a study published August 20 in JAMA.

Istaroxime, a dual action, luso-inotropic agent that’s still in clinical development, was granted fast-track designation by the FDA this month as a possible treatment for HFrEF.

An August 19 science advisory from the AHA states that a 4-gram dose of prescription omega-3 fatty acid medication can greatly reduce people’s triglyceride levels, but patients likely won’t see the same results if they turn to popular—yet unproven—fish oil therapies.

A single dose of the lipid-lowerer simvastatin, delivered to an organ donor pre-heart transplant, could decrease postoperative troponin levels in transplant recipients and protect the donor heart against perioperative myocardial ischemic damage.

A genetic predisposition for insomnia was linked to greater odds of heart disease and stroke—but not atrial fibrillation—in a study of more than a million people with or without CVD.

Fifteen states have now reported more than 120 cumulative cases of vaping-related lung disease or injury, according to the results of a CNN survey of state health departments.

A study published in Radiology August 20 suggests the harm of vaping tobacco products isn’t limited to nicotine itself, with users showing evidence of blood vessel damage even after smoking nicotine-free e-cigs.

The FDA on August 16 granted breakthrough designation to CVRx Inc.’s Barostim Neo System, a device meant to improve heart failure symptoms in patients unsuited for other therapies like CRT.